Clinical trial
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal…
NCT00372853 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00372853 |
|---|---|
| Title | Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma |
| Official title | A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | CP-675, 206, SU011248 |
| Enrollment | 28 |
| Start date | Nov 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Sep 7, 2006 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: